Log in

NASDAQ:ARNAArena Pharmaceuticals Stock Price, Forecast & News

$62.81
-1.27 (-1.98 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$62.27
Now: $62.81
$64.70
50-Day Range
$60.76
MA: $64.33
$68.51
52-Week Range
$32.95
Now: $62.81
$69.75
Volume409,000 shs
Average Volume667,739 shs
Market Capitalization$3.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Read More
Arena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$7.83 per share
Book Value$21.38 per share

Profitability

Net Income$397.55 million
Net Margins-5,727.22%

Miscellaneous

Employees194
Market Cap$3.62 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$62.81
-1.27 (-1.98 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

How has Arena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARNA stock has increased by 55.4% and is now trading at $62.81.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Arena Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arena Pharmaceuticals
.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Arena Pharmaceuticals
.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.42. Arena Pharmaceuticals had a negative return on equity of 31.14% and a negative net margin of 5,727.22%. During the same period in the prior year, the company posted ($1.24) EPS.
View Arena Pharmaceuticals' earnings history
.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

13 Wall Street analysts have issued twelve-month target prices for Arena Pharmaceuticals' stock. Their forecasts range from $56.00 to $95.00. On average, they expect Arena Pharmaceuticals' stock price to reach $76.75 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals
.

Has Arena Pharmaceuticals been receiving favorable news coverage?

Media headlines about ARNA stock have been trending very positive on Wednesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arena Pharmaceuticals earned a news impact score of 3.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Arena Pharmaceuticals
.

Are investors shorting Arena Pharmaceuticals?

Arena Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,160,000 shares, an increase of 11.3% from the December 31st total of 2,840,000 shares. Based on an average daily trading volume, of 381,200 shares, the days-to-cover ratio is currently 8.3 days.
View Arena Pharmaceuticals' Short Interest
.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), AT&T (T) and GW Pharmaceuticals PLC- (GWPH).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (1.22%), Macquarie Group Ltd. (0.91%), Candriam Luxembourg S.C.A. (0.90%), Rhenman & Partners Asset Management AB (0.42%), Asymmetry Capital Management L.P. (0.34%) and Swiss National Bank (0.25%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals
.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Asymmetry Capital Management L.P., Hussman Strategic Advisors Inc., Rhenman & Partners Asset Management AB, GW&K Investment Management LLC, Russell Investments Group Ltd., UBS Group AG, and Alps Advisors Inc.. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Christopher Cabell, Kevin Robert Lind, Manmeet Singh Soni, Randall E Woods, Robert Lisicki, Steven W Spector, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals
.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Great Lakes Advisors LLC, Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., WINTON GROUP Ltd, Swiss National Bank, AdvisorShares Investments LLC, and Quantitative Systematic Strategies LLC.
View insider buying and selling activity for Arena Pharmaceuticals
.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $62.81.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $3.62 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.